Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05656027 | Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia | PHASE3 | COMPLETED | 469 | — | — | Dec 19, 2022 | Jan 25, 2024 | May 13, 2026 | 25 | United States |
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1
| Arm | Type | Description |
|---|---|---|
| Aceclidine + Brimonidine (LNZ101) dosed bilaterally | EXPERIMENTAL | LNZ101 (Aceclidine /Brimonidine) ophthalmic solution |
| Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally | EXPERIMENTAL | LNZ100 (Aceclidine) ophthalmic solution |
| Brimonidine ophthalmic solution dosed bilaterally | EXPERIMENTAL | Brimonidine ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Aceclidine+Brimonidine combination ophthalmic solution | DRUG | LNZ101 (Aceclidine/Brimonidine) ophthalmic solution |
| Aceclidine ophthalmic solution | DRUG | LNZ100 Aceclidine ophthalmic solution |
| Brimonidine | DRUG | Brimonidine ophthalmic solution |
Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study visits; 3. Be 45-75 years...